Abstract
disease teaches us a number of lessons as it reveals factors and pathways implicated in the genesis of human pathology. For instance, diabetic renal damage is associated with a variety of stresses, e.g., glycemic stress resulting from hyperglycemia, oxidative stress from reactive oxygen species, carbonyl stress from reactive carbonyl compounds, and nitrosative stress from reactive nitrogen species. Proteins are particularly attractive targets for product analysis. Protein modifications are much more specific and stable biomarkers of the disease than lipids and other metabolites, and thus serve as footprints of biochemical processes. Their quantitative analysis not only facilitates better understanding of the physiopathology but also offers new therapeutic insight. In this review, we delineate oxidative protein modifications existing in diabetic nephropathy and discuss therapeutic perspectives towards the development of new classes of renoprotective agents. (Internal Medicine 42: 1165 -1171 , 2003 Key words: protein modification, advanced glycation end product, oxidative stress, carbonyl stress, renoprotection, anti-hypertensive agent
Is There Oxidative Stress in Diabetes?
In diabetes mellitus, the controversy has focused on the existence of an oxidative stress, its possible localization and relation to hyperglycemia, and its cause. Williamson et al (1) pointed out an increased cellular NADH/NAD+ ratio and suggested that diabetes is a state of "reductive stress" and "pseudo-hypoxia" rather than "oxidative stress". The presence of oxidative stress in diabetes rests on indirect evidence including increased ratios of NADP+/NADPH and of oxidized to reduced glutathibne, ascorbate, and albumin (2-4).
However, such imbalances in intracellular redox systems may be induced by non-oxidative mechanisms (e.g., the polyol pathway) and cause secondary alterations of sulfhydryl homeostasis, thus mimicking an oxidative stress (5). There is no a priori reason to conclude that these altera- The group of Baynes has first argued against the presence of a generalized oxidative stress in diabetes (6). These authors measure two oxidized amino acids in skin collagen, orthotyrosine and methionine sulfoxide.
They demonstrated an age-dependent increase in oxidative damage in skin collagen, pointing out that aging is indeed an oxidative stressdependent phenomenon. Surprisingly, the age-adjusted levels of oxidized amino acids in collagen proved virtually identical in both diabetics and non-diabetics. They thus concluded that diabetes is not associated with a generalized oxidative stress. On the other hand, we analyzed the protein modifications induced by carbohydrates and lipids occurring under oxidative stress and demonstrated the existence of a localized oxidative stress in diabetic nephropathy (7). Advanced glycation end products (AGEs) include a variety of molecular structures formed through different mechanisms. The formation of two well-known AGEs, pentosidine (8) and A^-(carboxymethyl)lysine (CML) (9), depends not only on glycation but also, to a greater extent, on oxidation (10). By contrast, pyrraline, another AGE, is formed only through a glucosedependent but oxidative stress-independent mechanism (1 1). Should tissue AGE formation depend only on hyperglycemia, all AGE structures should be detected in diabetic glomerular lesions. The results indicate that pentosidine and CML are identified in early mesangial expansion as well as in advanced nodular deposits, together with protein modifications derived from oxidation of lipids or amino acids (7, 12) . By contrast, pyrraline is absent in diabetic glomeruli but readily identified in the interstitium. The existence of a localized oxidative stress has been confirmed in diabetic vascular lesions by the group of Heinecke (13).
In vascular lesions of streptozotocin-induced diabetic monkey, levels of ortho-tyrosine, m^ta-tyrosine, and dityrosine, all of which are protein modifications by hydroxyl and tyrosyl radicals, are significantly higher in diabetics than non-diabetics. Interestingly, these levels are correlated with hemoglobin Ale, suggesting a link between hyperglycemia a nd oxidative stress. These findings altogether suggest that diabetes is not associated with a generalized oxidative stress, but with a localized oxidative stress (e.g., glomerular and vascular lesions).
Various Oxidative Pathways and Their Protein Modifications
In vivo, oxidative protein damage present in diabetic nephropathy is a complex phenomenon. It involves many factors and pathways as illustrated in Fig. 1 (Fig. 3) Olmesartan and atenolol given to SHR/ND mc-cp (fat/fat) normalize systolic blood pressure to the same extent. However, only olmesartan reduces AGE renal content and successfully decreases proteinuria. Atenolol, by contrast, modifies neither renal AGE content nor proteinuria.
In this model at least, these findings fit with the concept that some renal benefits of ARB are independent of blood pressure l owering but closely linked to AGE reduction (Table 1) . Contrary to atenolol, hydralazine significantly reduces the renal tissue pentosidine content and improves diabetic renal damage (28). The effect of hydralazine (5 mg/kg/day) on albuminuria and glomerular damage, although not statistically significant, is similar to that observed with the low olmesartan dosage (1 mg/kg/day), the blood pressure reduction being similar in the 2 groups. Renal protection appears thus independent of any interference with the RAS. Altogher, these results suggest that the added benefits of ARB in clinical trials may not be necessarily related to their ability to interfere with the RAS but might rather reflect an i nhibition of AGE formation.
These considerations provide ,a framework to understand the additional benefits described in clinical studies of ARB in type 2 diabetics (31, 32 
Future Prospects
Wehave thus far characterized the AGE lowering profile of several thousands of chemical compounds including currently used medical drugs. Three classes of novel structures (not hydrazine-derivatives like aminoguanidine or ALT-946) have been identified that efficiently inhibit in vitro AGE formation: they are much more powerful and structurally different from the first generation AGE inhibitors, and do not trap pyridoxal.
Several promising hit/lead compounds are now under investigation.
Some of them decrease proteinuria efficiently in SHR/NDmc-cp without concomitant blood pressure and glucose lowering. We still have to synthesize their derivatives, optimize their structures, and test their effectiveness in preclinical studies. The development of these new drugs raises significant hopes to prevent or at least to slow down the development of diabetic nephropathy. 
